Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vodafone Group PLC M&A Activity 2020

Apr 1, 2020

5275_rns_2020-04-01_81df5e22-c6a1-4e1e-8187-c4e1848b8d79.html

M&A Activity

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3124I

Vodafone Group Plc

01 April 2020

1 April 2020

VODAFONE COMPLETES SALE OF VODAFONE MALTA

Further to the announcement on 19 December 2019, Vodafone Group Plc announces it has completed the sale of 100% of Vodafone Malta to Monaco Telecom SAM for a cash consideration equivalent to an Enterprise Value of €250 million, implying FY19 multiples of 7.8x EBITDA and 13.1x OpFCF1.

1. Defined as EBITDA minus capex

- ends -

For further information:

Vodafone Group

Media Relations Investor Relations
www.vodafone.com/media/contact [email protected]

About Vodafone Group

Vodafone Group is one of the world's leading telecoms and technology service providers. We have extensive experience in connectivity, convergence and the Internet of Things, as well as championing mobile financial services and digital transformation in emerging markets.

Vodafone Group has mobile operations in 24 countries, partners with mobile networks in 42 more, and fixed broadband operations in 19 markets. As of 31 December 2019, Vodafone Group had approximately 625 million mobile customers, 27 million fixed broadband customers and 22 million TV customers, including all of the customers in Vodafone's joint ventures and associates. For more information, please visit: www.vodafone.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DISEAXDFDAEEEFA